Hungarian pharmaceutical group Egis Rt said it will raise its sales by more than a quarter on CIS markets, according to Bluebull. The figure will likely top its predicted 20 percent growth in central and eastern European states, and exceed the eight percent rate Egis expects to report in Hungary in its current fiscal year, which will end September 30, 2003. The company said sales in western Europe and the US will increase by USD 1 million. Deputy CEO for Finances Laszlo Marosffy said domestic sales will climb 3.2 percent because of higher drug prices. Egis said it will introduce six new drugs in the coming months. Three of these may generate sales of HUF 400 million each for the company, Marosffy added.